Melanoma Cancer Device

Outside UK, Guernsey MedTech, Melanoma, Apple, Health Industry, Unique patented software

Short Summary

Melanoma Cancer is a killer, whose incidence is growing worldwide. The global costs of diagnosis and treatment are measured in $billions annually. Application of the nomela device will reduce costs dramatically, generating significant profits.

Highlights

  • 10 year development of unique software to address global melanoma cancer
  • Application in $multi-billion world markets, USA, Europe, Nordics, Aus/NZ
  • Huge cost savings using nomela. Working testable, Apple prototype in play
  • From which very significant profits can be generated + patient benefits
  • Leading to exit via sale to MedTech/Pharma company, or flotation

Overview

Target
£2,000,000
Minimum
£100,000
Invested
n/a
Previous Rounds n/a
Stage Finished Product
Investor Role Any
Please Note: Investments of this nature carry risks to your capital as well as potential rewards. Please read our Risk Warning and Disclaimer before deciding to invest.

Sign up or log in now

Sign up now to gain full access to pitches and investor profiles

global:publish_msg_immediate




global:publish_msg



Congratulations!


You have passed the test and you may continue your with your investment.